# Biotectix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotectix

- Industry: Healthcare
- Headquarters: Ann Arbor, US
- Website: www.biotectix.com
- Total disclosed funding: $0.8M
- Latest round: Series A (Feb 1, 2007)
- Investors on record: 1

## About

Biotectix specializes in the development of innovative electrode coatings that enhance medical device performance. Their flagship product, Amplicoat®, significantly improves the functionality of electrodes used in medical applications, providing a vital service to the healthcare industry.Founded in 2007 in Ann Arbor, US, Biotectix focuses on advancing conductive polymer coating technologies. The company has engaged in two funding deals, with the most recent being a GROWTH round in September 2010, raising USD 3.000 mn from Allied Minds. Sarah Richardson-Burns is the founder of Biotectix, establishing a venture that aims to enhance medical technologies.Biotectix specializes in advanced conductive polymer coating technology, primarily through its flagship product, Amplicoat®. This innovative coating technology enables the miniaturization of electrodes without compromising signal quality, enhancing the interaction between electrodes and human tissue. Amplicoat® improves critical parameters such as electrode impedance and charge injection capabilities, making it particularly beneficial for applications in electrophysiology and neuromodulation. The coatings are applicable to various medical electrode materials, including platinum, iridium, gold, and titanium, and are designed to streamline the manufacturing process while ensuring biocompatibility. Biotectix serves a diverse client base that includes medical device manufacturers and research organizations across North America, Europe, and Asia.Biotectix generates revenue primarily through B2B transactions, supplying its Amplicoat® technology to medical device manufacturers and industry partners. The business model revolves around direct sales of products, along with potential collaborations and contracts for custom applications tailored to client specifications. Pricing is determined by the complexity and scale of the required coatings, positioning Biotectix to effectively engage with clients seeking to enhance their product functionality and establish solid business relationships.Biotectix is focused on expanding its offerings and market reach, with plans to develop new products enhancing electrode performance. Additionally, the company aims to penetrate new markets and geographic regions, targeting specific opportunities in Europe and Asia by 2015. The recent GROWTH round funding of USD 3.000 mn will support these initiatives, allowing Biotectix to invest in product development and market expansion efforts.

## Funding rounds

- Series A, Feb 1, 2007, $0.8M — Allied Minds

## Investors

- Allied Minds (https://capitalatlas.ai/funds/allied-minds) — Series A